PARIS : France’s Atos aims to double its international market share in supercomputing to about 16per cent by round 2026, one in every of its government mentioned, stepping up European competitors in a subject dominated by the United States and China.
The know-how and IT consulting agency introduced on Wednesday a brand new technology of supercomputer, dubbed BullSequana XH3000, in a position to carry out up to one billion operations per second.
This stage of calculation capability will assist with challenges starting from simulating the consequences of latest medicine and nuclear fission to forecasting climate and local weather change, it mentioned.
“It’s basically like a chassis that will carry any engine, and link it to other chassis in order to carry more load,” mentioned Arnaud Bertrand, the top of technique and innovation at Atos’ cybersecurity and supercomputing unit BDS.
Bertrand mentioned Atos was aiming to double its international market share in supercomputing over the following three to 4 years from about 8per cent presently. The group does not disclose its monetary targets for the exercise.
Atos’s supercomputer, designed and made in the town of Angers in western France, delivers six occasions extra computing energy than its earlier model, the corporate mentioned.
Today’s heavyweights in supercomputing are U.S. agency Hewlett Packard Enterprise and China’s Lenovo Group, Bertrand mentioned. Other rivals embody China’s Sugon and Japan’s Fujitsu.
Atos is the one main European producer of so known as excessive efficiency computing merchandise (HPC), a know-how deemed strategic by France and the European Union, which co-finances EuroHPC, a three way partnership between European international locations and personal organisations.
EuroHPC is one in every of Atos’ prime three shoppers, together with France’s atomic vitality fee CEA and the federal government of India.
Key elements of Atos’ supercomputers nonetheless come from Asia and the United States, nonetheless. The group is aiming to relocate a part of the manufacturing in Europe, Bertrand mentioned.
“We can’t ask China and the United States for their authorization if tomorrow we want to know the impact of human activity on climate or if we want to develop the next generation of drugs,” he mentioned.
(Reporting by Mathieu Rosemain; Editing by Mark Potter)